univers coverag
calendar event
medacorp puls call complic compound resurg
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
fda adcom anesthet analges drug product
american committe treatment research multipl sclerosi intern societi
technolog arthroplasti nation hemophilia foundat american societi
dermatolog surgeri european associ neuro-oncolog
util price capital-expenditure spend trend combin believ
posit overal intra-qtr commentari investor confer management team rais
prospect beat rais least in-lin better result compani across univers
howev believ larg expect investor solid med-tech print key question
whether solid qtli perform met sell-the-new buy-the-new reaction sector
experienc widen valuat premium vs throughout year recent
pullback market creat better set-up margin still think growth/momentum
name last week bear brunt sell-off appear trade
group -- -depend whether growth favor -- -which make gaug stock reaction
company-specif event even posit tougher view type name
backdrop inclin posit stock improv fundamentals/beat rais
potenti plu expens rel basi run-up much name
group op op op op op view less riski growth
inclin stay posit wed character riskier growth -- -and take advantag
recent sell-off growth stock -- -we recommend name highest convict upward estim
revis potenti op op op op op op
survey suggest normal season growth step-up anticip would expect
respond project big pick-up ntm growth project gener in-lin ltm
hip/kne spine robot increas spend prioriti vs prior survey leav us increment
posit rise robot placement prospect current leader ortho robot includ mako
cardio volum suggest upsid despit season like larg reflect
implic hips/kne survey highlight typic season y/i growth step-down consist
comp adj us market project re-acceler neutral datapoint
implic spine us market might turn corner
survey yoy util slow shift op posit mco op/
bottom line result octob medacorp survey hospit administr
gaug util trend driver point deceler yoy util trend across site
servic ip inpati op outpati ambulatori surgeri center ed emerg
depart continu mix shift lower cost op site servic result
support posit outlook coverag benefit deceler yoy util mix
shift lower cost op set expect stabl procedure-specif price despit
survey data support continu moder cost trend per capita view op pois
solid quarter given view superior adapt balanc capit deploy
strengthen posit exist market allow entri attract new market broadli
volum remain weak expect facil alreadi reflect challeng
season weakest quarter easier hurrican comp offer greater warn achiev
optum-unh op op op continu benefit tailwind mix shift
respond show chang capital-expenditure next twelv month ntm given
not-for-profit nfp natur respond set expect tax reform tailwind level play
field increas capital-expenditure spend led
medacorp conduct quarterli survey hospit administr septemb gaug
procedur util trend driver inpati outpati ambulatori care set along
shift care deliveri set procedur
survey result indic yoy deceler util trend across site servic
trend remain posit mco
despit survey data support continu moder cost trend per capita view
pois solid quarter given view superior adapt balanc capit deploy
across organ capital-expenditure toward servic line ambulatori access point even inpati asset
strengthen posit exist market allow entri attract new market broadli
volum remain weak expect facil alreadi reflect challeng season
weakest quarter easier hurrican comp offer greater warn achiev exhibit
respond group indic continu mix shift lower cost op set
procedure-specif util trend remain larg steadi
procedure-specif rate also remain steadi
age popul import driver util ntm
around respond indic chang capital-expenditure next twelv month
show increas
bottom line publish individu one-pag compani preview ortho
supplies/ cap equipment/oth elgx
compani preview follow includ detail view around expect set-up head
print well views/stanc stock
inclin posit stock improv fundamentals/beat rais potenti plu
expens rel basi run-up much name group
inclin posit growth/momentum prefer pick would op
controversi set-up among small-cap univers op op
ep includ tax impact exclud tax impact ep would
bd stand-alone onward new co inclus bcr oper deal close
revenu million
ep adjust stock split
bottom line publish individu one-pag compani preview cardio
ew nvcn large-cap diversifi diabetes/oth
individu compani preview follow includ detail view around expect setup head
print well view/stanc stock
context believ bit risk-off trade on-going flight safeti expect
gener large-cap outperform smid-cap earn
highest convict beat rais name setup flight safeti environ
favor investor look consist growth reason valuat mp op
op op op mid/large-cap op op small-cap
expect good quarter possibl even beat rais either growth feel less safe
valuat still high rel basi even recent pullback
expect seem low stock could react posit posit news/even margin
see biggest risk estim and/or stock-specif issu could pressur share
regardless print ew mp nvcn op
detail includ insid
revenu million ep ex item amort
revenu mm dilut gaap ep
bottom line despit yoy deceler hospit survey view acut facil
report in-line quarter given elev price expect remain near-term
easi comp given lesser impact hurrican believ least come line
potenti beat even rais full year recent deal integr pull
bottom line could continu face near-term volum pressur detroit
medic ctr il hospit view conif sale remain track volum expect
remain soft averag flat survey report util
increas view lack meaning hurrican disrupt provid cushion
easier comp price remain controversi expect elev price persist near-term
normal long-term consensu point increas averag cost
staf wage pressur off-set cost control especi mm cost save
program headwind persist recent sell price blow
view though stock recov nice last week expect
line guidanc acut management still expect bh revenu rebound tax reform
offer tailwind toward level play field profit
competit servic line improv access point remain bullish
best breed must facil name special situat name see broader
market sell-off strong buy opportun
investor expect view much in-line expect
could posit catalyst upsid
medacorp survey result indic util trend deceler yoy across inpati ip
outpati op ambulatori surgeri center line qoq shift ambulatori
price remain controversi expect strong price driven increas acuiti optim
commerci mix could off-set volum weak continu normal
side swb salari wage benefit oper expens expect improv
despit wage pressur due proactiv cost control oper expens stabil reflect
guidanc consensu exhibit
 remain highli lever progress made reduc leverag
behavior season weak qtr us uk pressur remain
much smaller uk footprint ebitda
bottom line analysi bonu releas oct point clear
win mp hnt plan enter back rate nice improv
op improv wcg op ci op declin aet op op
op declin clearli acquisit america first choic health sun membership
fulli expect improv upon integr acquir asset op see
chang yet membership rate plan
announc rate oct percentag rate membership translat
directli margin improv and/or membership gain given associ bonu rate
perform overal industri line
clear winner increas membership upgrad hnt
plan
see impress increas membership mm
member show continu improv busi
wcg also see decent improv membership
ci rate membership increas plan rate
see membership declin
rate membership declin modestli
aet see declin membership
rate membership expect remain flat
personnel chang aet/cv heel doj clearanc
bottom line announc key personnel chang heel doj condit
approv aet/cv merger pend divestitur aet part membership wcg
addit three new bod member shawn guertin cfo aet formerli announc cfo
combin compani leav june eva boratto current control chief
account offic take role cfo combin aet/cv manag
view departur aet cfo shawn guertin announc today link togeth
departur cfo david denton could pose challeng given complex price
underwrit aet busi amid consider integr challeng mr guertin stay
june mr denton schedul depart close transact accord
initi announc combin manag team link
aet cfo shawn guertin depart june
doj clear cvs/aet transact today
press releas also announc new addit board director
new hix state increas membership exposur
bottom line increas hix membership revenu potenti also margin
risk exchang pressur enter new state pa nc sc tn expand
footprint link hix enrol steadi link driven
organ revenu growth far year though may see increas competit
exist player includ blue new entrant size market entri yet
disclos new state overal repres around total hix enrol bring
hix presenc state expand hix presenc offer membership top-lin growth
potenti margin downsid manag state hix margin guidanc
upper end rang upcom catalyst includ earn enrol
season medicaid hix medicar advantag
excel result doj grant deal approv follow part
bottom line doj approv cvs-aet deal excel result sharehold
remain confid abil execut plan creat new front door
healthcar encourag doj found addit competit concern follow
settlement ensur divestitur aet part busi link believ deal close
year-end consist manag guidanc remain one top pick given
strong market posit posit outlook strategi post-merg
bottom line see buy opportun today competit liquid biopsi lbx
screen poster present freenom yesterday on-going american
colleg gastroenterolog confer abstract data poster
releas prior month like known investor believ freenom leadership
team extrem compet compar gi present cellmax taiwan pi
earlier year test still development stage full patient sampl
data ai-emerg present believ data potenti
far meaning assess long-term success lbx test still commerci
test long road investor watch year number
hurdl includ pivot trial fda approv inclus guidelin reimburs
commerci payer one one final commerci adopt one alreadi see heavi
lift effort -pfe agreement rule possibl open
review opportun liquid biopsi lbx competitor test data look promis
current hold cash
cvs/aet like close earli doj announc clearanc
bottom line merger op /aet mp like close earli today doj
announc sale aet medicar part pdp busi wcg op would fulli
resolv doj competit concern link aet wcg previous announc divestitur
clear major regulatori hurdl cvs/aet enabl like close earli pend
remain state review also provid wcg ep accret estim per share
divestitur fund cash hand wcg disclos mm
aet see price immateri financi cvs/aet transact larg driver
transform mco/pbm landscap toward manag perspect
see virtual end stand-alone pbm model deal close signal necessari chang
busi model integr medic rx benefit take hold risk bear align employ
govern end custom op medicare-focus pbm offer fifth
 methodolog dcf discount rate termin growth rate
reimburs overnight sinuva still matter
impli ev/sal
hurrican michael exposur manag ebitda
nolasiban safeti data continu support strong clinic profil
product price contribut growth grow
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
clovi present data rubraca phase studi poster
discuss session esmo cest edt
trial evalu rubraca monotherapi refractory/relaps metastat castrat
resist prostat cancer mcrpc patient fail prior next-gener
androgen receptor target therapi one line taxan base chemo
dataset expect includ patient roughli brca patient
brca patient expect evalu recist respons
focu expect recist respons rate data regulatori
endpoint need consider acceler approv note receiv
breakthrough therapi design base data suggest data
esmo like compel link recent note
trial lead approv prostat cancer rubraca could first parp gain
indic link initi
indic compani could file acceler approv prostat
cancer base data
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
recent note abstract releas adap -- flash esmo abstract disclos
increment safeti data esmo outperform
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
present phase ii data tazemetostat epithelioid sarcoma es also
ini tumor cohort
initi approv tazemetostat could es drug demonstr
respons rate diseas control rate rare sarcoma littl
updat data expect esmo compani expect present durat
respons data key fda assssment respons rate data
regulatori file expect mild delay origin guidanc
compani resolv partial clinic hold
es small indic modest fundament valu peak us revenu
risk-adjust npv probabl success approv could
help de-risk larger opportun especi light recent partial clinic hold
potenti safeti regulatori concern link
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
note -- flash littl new data disclos esmo abstract present
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
like provid addit detail around launch prepar nyzyra
manag may also releas price detail nuzyra omadacyclin acut bacteri
skin skin structur infect abssi commun acquir bacteri pneumonia
capb well date launch
model roughli iv oral indic
continu see nuzyra grow sale
recent note addit thought nuzyra approv rais pt
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
fda adcom anesthet analges drug product
fda adcom joint gastrointestin drug drug safeti risk
pdufa dupix moder sever asthma adult adolesc
fda adcom scienc board fda
fda adcom endocrinolog metabol drug
fda adcom joint psychopharmacolog drug drug safeti risk
fda adcom vaccin relat biolog product
pdufa revefenacin lama copd
fda adcom anesthet analges drug product roxicodon
pdufa roxicodon abuse-deterr formul immediate-releas single-
epo decis ip tsro
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american committe treatment research multipl sclerosi
intern societi technolog arthroplasti
american societi dermatolog surgeri
european associ neuro-oncolog
american associ blood bank
american societi anesthesiologist
european associ nuclear medicin
european societi gene cell therapi
american societi human genet arql
american colleg dentist
european associ cardiothorac surgeri
european societi medic oncolog adap link asln
cest imdz link iph loxo
american colleg rheumatolog
canadian associ pediatr health centr
colleg american pathologist
american societi therapeut radiolog oncolog
american colleg surgeon
american academi child adolesc psychiatri
american societi nephrolog kidney week achn
clinic trial alzheim diseas
american academi physic medicin rehabilit
american academi ophthalmolog
american academi periodontolog
american colleg prosthodontist
associ molecular patholog
american associ scienc
societi immunotherapi cancer
intern confer societi medic innov technolog
intern societi traumat stress studi
american associ studi liver diseas
american societi cytopatholog
model model recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
biopharma price pledg made biopharma what happen
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
biopharma novel pain treatment class bar far limit potenti
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco kol see distinct pt address vascepa reiter greater need
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic suppli devic la med-tech day deep dive physician view
medic devices-cardiolog hr takeaway cabana unlik chang af practic
medic devic survey support market share re-gain assumpt
medic suppli devic initi takeaway sage robot continu gain
medic devic leerink healthcar confer panel devic penetr set
biopharma product price contribut growth grow
biopharma price pledg made biopharma what happen
biopharma minim impact script npf chang could other follow
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut state auditor report seem show competit price
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
initi coverag target oncolog
initi fine-tun btk autoimmun
perform
outperform
 research micro-dystrophin
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
 cll survey suggest signific opp next-gen btk improv
 medacorp payor survey highlight favor statu quo intact orphan
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 medacorp survey highlight driver headwind ali pt outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
 survey confirm bullish view adcetri frontlin hl reiter op pt
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
